Study Spotlights
Top Recruiter
--
Top Recruiter --
A Phase 2 Atopic Dermatitis Study
Trial Precision helped Equity Medical become the top recruiter nationally with 8 enrolled subjects during a 3-month period.
-
Screens: 10 patients
Enrolled Patients: 8 patients
Screen Fail Rate: 20%
Timeframe: 3 months
-
Indication: Atopic Dermatitis
Sponsor: Apogee Therapeutics, Inc
Study: APG777-201
Phase: Phase 2
Top Recruiter
--
Top Recruiter --
A Phase 2 Alopecia Areata Study
Trial Precision helped Equity Medical become the top recruiter nationally with 6 enrolled subjects during a 3-month period, with a 0% screen fail rate.
-
Screens: 6 patients
Enrolled Patients: 6 patients
Screen Fail Rate: 0%
Timeframe: 3 months
-
Indication: Alopecia Areata
Sponsor: Q32 Bio Inc
Study: ADX-914-203
Phase: Phase 2
Top Recruiter
--
Top Recruiter --
A Phase 3 Hidradenitis Suppurativa (HS) Study
Trial Precision helped Equity Medical become the top recruiter nationally with 9 enrolled subjects during a 3-month period. Additionally, was able to find 5 subjects with TNF-failures.
-
Screens: 12 patients
Enrolled Patients: 9 patients
Screen Fail Rate: 25%
Timeframe: 3 months
-
Indication: Hidradenitis Suppurativa (HS)
Sponsor: Avalo Therapeutics, Inc.
Study: AVTX009-HS-201
Phase: Phase 3
Top Recruiter
--
Top Recruiter --
A Phase 2 Chronic Spontaneous Urticaria Study
Trial Precision helped Equity Medical become the top recruiter nationally with 6 enrolled subjects during a 3-month period.
-
Total Screens: 8
Enrolled Subjects: 6
Screen Fail Rate: 25%
Timeframe: 3 months
-
Indication: Chronic Spontaneous Urticaria + Inducible Urticaria study
Sponsor: Blueprint Medicines Corp.
Study: BLU-808-1201
Phase: Phase 2
A Phase 2 Atopic Dermatitis Study
Trial Precision helped Equity Medical enroll 4 subjects in a 4-week period with a 0% screen fail rate, demonstrating a rapid success story.
-
Total Screens: 4
Enrolled Subjects: 4
Screen Fail Rate: 0%
Timeframe: 4 weeks
-
Indication: Atopic Dermatitis
Sponsor: Aclaris Therapeutics, Inc.
Study: ATI-045-AD-201
Phase: Phase 2
A Phase 3 Plaque Psoriasis Study
Trial Precision helped Equity Medical enroll 6 subjects during a 4-week period
-
Screens: 10 patients
Enrolled Patients: 6 patients
Screen Fail Rate: 40%
Timeframe: 4 weeks
-
Indication: Plaque Psoriasis
Sponsor: Alumis
Study: ESK 001-017
Phase: Phase 3